Dulaglutide versus insulin effects on metabolism and artery disease risk in teenagers with thalassaemia-related diabetes

Dulaglutide may have beneficial effects on glycaemic metrics and iron load in adolescents with TDT-induced diabetes.

• Chronic iron overload is linked to serious health issues like diabetes and cardiovascular diseases in transfusion-dependent beta-thalassemia.
• Dulaglutide is a glucagon-like peptide-1 receptor agonist approved for treating type 2 diabetes and cardiovascular diseases.
• This assessment focuses on comparing dulaglutide to conventional insulin therapy regarding its effects on blood sugar levels and pancreatic function.
• The study also aims to evaluate the impact of dulaglutide on iron levels and lipid profiles in affected adolescents.

Simplified